Valeant posts loss on Medicis buyout costs; Cipla hikes offer for Cipla Medpro to $512M;

@FiercePharma: Trending: Top 10 Pharma Advertising Budgets - 2012. Special Report | Follow @FiercePharma

@EricPFierce: U.S. Supreme Court ruling against Amgen in class action investor case seen as hit to Pharma, other businesses. Story | Follow @EricPFierce

> Valeant Pharmaceuticals ($VRX) swung to a loss in the fourth quarter, thanks to charges related to its Medicis Pharmaceutical buyout. Report | Release

> Indian generics maker Cipla hiked its offer for South Africa's Cipla Medpro by 17%, bringing its bid to $512 million. Report

> Lundbeck won European approval for Selincro, a treatment for alcohol dependency that's key to the Danish drugmaker's growth strategy. Report

> Ipsen posted a full-year loss of €29 million ($37.9 million) after pulling out of the hemophilia treatment market. Report

> An Indian court put Cadila Pharmaceuticals on notice after the drugmaker failed to raise employees' salaries as ordered by an industrial tribunal. Report

Biotech News

 @FierceBiotech: Ignyta, Lieden University team on rheumatoid arthritis biomarker research. Item | Release | Follow @FierceBiotech

@JohnCFierce: Sarepta spikes on disputed report of adverse events for rival GSK drug. Story | Follow @JohnCFierce

@RyanMFierce: Is Africa poised to play a bigger role in drug innovation? From Novartis: More | Follow @RyanMFierce

> Merck's Tredaptive fiasco blamed on adverse reactions to niacin. Article

> Langer biotech Kala earmarks $11.5M round for next-gen ophthalmology drugs. More

> Takeda snags rights to lupus drugs from Seattle upstart in $255M deal. News

Medical Device News

 @FierceMedDev: FDA: Spending cuts will delay product approvals. Item | Follow @FierceMedDev

 @MarkHFierce: Fierce 15 company CardioKinetix nailed down the second half of a $44M Series E. News | Follow @MarkHFierce

 @DamianFierce: Have a look at @FierceMedDev's top 10 moneymakers in medical devices. Special Report | Follow @DamianFierce

> Medtronic scores CE mark for novel TAVI valve. News

> Sorin commits $5M more to Israeli heart failure device startup, with option to buy. More

> Natus predicts 20% revenue soar in 2013. Article

Vaccines News

> FDA panel endorses quadrivalents, setting stage for new flu market. Article

> Is it too soon to quit on Nabi's nicotine vaccine? More

> Seasonal flu vaccine only 56% effective. Story

> GSK facing competition from Sanofi's 6-in-1 shot. Item

> After rejection, Dynavax to shoot for limited hep B vaccine approval. Report

Pharma Manufacturing News

> Ranbaxy problems overshadow manufacturing expansion. Article

> Qualicaps adds new technology as part of expansion. Item

> FDA warning to Abbey questions quality of API for sterile drugs. Story

> Hospira manufacturing problems arise at an inopportune time. More

And Finally... Autism shares genetic features with four other psychiatric disorders, including bipolar disorder and schizophrenia. Report

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.